| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3127c0ebee3f865b211b019fac84286 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001129
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2018-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9422268be94051a036f7771d816b19bc |
| publicationDate |
2019-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019018382-A1 |
| titleOfInvention |
COMPOSITIONS AND METHODS FOR TARGETING CANCERS EXPRESSING CD33 |
| abstract |
The present invention provides compositions and methods for the targeted treatment of CD33 expressing cancers. In particular, the present invention provides chimeric antigen receptor (CAR) polypeptides that can be used with adoptive transfer of cells to target and eliminate CD33 expressing cancers. The invention also relates to immune effector cells, such as T lymphocytes or natural killer (NK) cells, which are modified to express these CARs. Therefore, the invention also relates to methods for creating antitumor immunity in a CD33-expressing cancer subject, which involves adoptive transfer of the described modified immune effector cells to express the described CARs. In particular, the present invention relates to multivalent antibodies capable of causing T cells to destroy CD33 expressing malignant cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019177986-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020198678-A1 |
| priorityDate |
2017-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |